167 related articles for article (PubMed ID: 14675542)
1. Mycobacterium tuberculosis: a model system for structural genomics.
Smith CV; Sacchettini JC
Curr Opin Struct Biol; 2003 Dec; 13(6):658-64. PubMed ID: 14675542
[TBL] [Abstract][Full Text] [Related]
2. Advances in Mycobacterium tuberculosis structural genomics: investigating potential chinks in the armor of a deadly pathogen.
Chim N; McMath LM; Beeby M; Goulding CW
Infect Disord Drug Targets; 2009 Nov; 9(5):475-92. PubMed ID: 19594421
[TBL] [Abstract][Full Text] [Related]
3. Assessing the progress of Mycobacterium tuberculosis H37Rv structural genomics.
Fang Z; van der Merwe RG; Warren RM; Schubert WD; Gey van Pittius NC
Tuberculosis (Edinb); 2015 Mar; 95(2):131-6. PubMed ID: 25578513
[TBL] [Abstract][Full Text] [Related]
4. The potential impact of structural genomics on tuberculosis drug discovery.
Arcus VL; Lott JS; Johnston JM; Baker EN
Drug Discov Today; 2006 Jan; 11(1-2):28-34. PubMed ID: 16478688
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach.
Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A
Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549
[TBL] [Abstract][Full Text] [Related]
6. The tuberculosis structural genomics consortium: a structural genomics approach to drug discovery.
Musa TL; Ioerger TR; Sacchettini JC
Adv Protein Chem Struct Biol; 2009; 77():41-76. PubMed ID: 20663481
[TBL] [Abstract][Full Text] [Related]
7. Structural genomics of Mycobacterium tuberculosis: a preliminary report of progress at UCLA.
Goulding CW; Perry LJ; Anderson D; Sawaya MR; Cascio D; Apostol MI; Chan S; Parseghian A; Wang SS; Wu Y; Cassano V; Gill HS; Eisenberg D
Biophys Chem; 2003 Sep; 105(2-3):361-70. PubMed ID: 14499904
[TBL] [Abstract][Full Text] [Related]
8. Structural genomics approach to drug discovery for Mycobacterium tuberculosis.
Ioerger TR; Sacchettini JC
Curr Opin Microbiol; 2009 Jun; 12(3):318-25. PubMed ID: 19481971
[TBL] [Abstract][Full Text] [Related]
9. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
10. Unraveling the potential of intrinsically disordered proteins as drug targets: application to Mycobacterium tuberculosis.
Anurag M; Dash D
Mol Biosyst; 2009 Dec; 5(12):1752-7. PubMed ID: 19763328
[TBL] [Abstract][Full Text] [Related]
11. Structure-based approaches to drug discovery against tuberculosis.
Holton SJ; Weiss MS; Tucker PA; Wilmanns M
Curr Protein Pept Sci; 2007 Aug; 8(4):365-75. PubMed ID: 17696869
[TBL] [Abstract][Full Text] [Related]
12. Structural biology and biochemistry of cytochrome P450 systems in Mycobacterium tuberculosis.
McLean KJ; Munro AW
Drug Metab Rev; 2008; 40(3):427-46. PubMed ID: 18642141
[TBL] [Abstract][Full Text] [Related]
13. An overview to understand the role of PE_PGRS family proteins in Mycobacterium tuberculosis H37 Rv and their potential as new drug targets.
Meena LS
Biotechnol Appl Biochem; 2015; 62(2):145-53. PubMed ID: 24975480
[TBL] [Abstract][Full Text] [Related]
14. Protein targets for structure-based anti-Mycobacterium tuberculosis drug discovery.
Lou Z; Zhang X
Protein Cell; 2010 May; 1(5):435-42. PubMed ID: 21203958
[TBL] [Abstract][Full Text] [Related]
15. The progress made in determining the Mycobacterium tuberculosis structural proteome.
Ehebauer MT; Wilmanns M
Proteomics; 2011 Aug; 11(15):3128-33. PubMed ID: 21674801
[TBL] [Abstract][Full Text] [Related]
16. PhoP, a key player in Mycobacterium tuberculosis virulence.
Ryndak M; Wang S; Smith I
Trends Microbiol; 2008 Nov; 16(11):528-34. PubMed ID: 18835713
[TBL] [Abstract][Full Text] [Related]
17.
Nunes JES; Duque MA; de Freitas TF; Galina L; Timmers LFSM; Bizarro CV; Machado P; Basso LA; Ducati RG
Molecules; 2020 Mar; 25(6):. PubMed ID: 32168746
[TBL] [Abstract][Full Text] [Related]
18. Comparing isogenic strains of Beijing genotype Mycobacterium tuberculosis after acquisition of Isoniazid resistance: A proteomics approach.
Nieto R LM; Mehaffy C; Dobos KM
Proteomics; 2016 May; 16(9):1376-80. PubMed ID: 26929115
[TBL] [Abstract][Full Text] [Related]
19. Mycobacterium tuberculosis H37Rv LpqG Protein Peptides Can Inhibit Mycobacterial Entry through Specific Interactions.
Sánchez-Barinas CD; Ocampo M; Vanegas M; Castañeda-Ramirez JJ; Patarroyo MA; Patarroyo ME
Molecules; 2018 Feb; 23(3):. PubMed ID: 29495456
[No Abstract] [Full Text] [Related]
20. Novel targets in M. tuberculosis: search for new drugs.
Lamichhane G
Trends Mol Med; 2011 Jan; 17(1):25-33. PubMed ID: 21071272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
